Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inter Parfums 2007 guidance

This article was originally published in The Rose Sheet

Executive Summary

Firm projects sales of $365 mil. in 2007, a 19% increase over its mid-range expectation ($305.5 mil.), while net income for the year is anticipated to be $20.4 mil., 21% higher than previously announced, according to a Nov. 27 release. "The coming year is slated to be an important one for top and bottom line growth," CEO Jean Madar states. Through a partnership announced in October, Inter Parfums will be promoting jeweler Van Cleef & Arpels' First and Tsar scents, along with an entirely new fragrance line. The company will introduce new women's fragrances under Christian Lacroix and S.T. Dupont in the spring, followed by new offerings from Roxy and Paul Smith in the fall. Also in 2007, the company will begin to roll out its Gap fragrances and personal care products (1"The Rose Sheet" July 25, 2005, p. 3)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel